Marcade G, Deschamps C, Boyd A, Gautier V, Picard B: Replicon typing of plasmids in Escherichia coli producing extended-spectrum beta-lactamases. J Antimicrob Niraparib Chemother 2009, 63:67–71.PubMedCrossRef 40. Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y:

selleck screening library Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother 2008, 61:1003–1006.PubMedCrossRef 41. Dahmen S, Mansour W, Boujaafar N, Arlet G, Bouallegue O: Distribution of cotrimoxazole resistance genes associated with class 1 integrons in clinical isolates of Enterobacteriaceae in a university hospital in Tunisia. Microb Drug Resist 2010, 16:43–47.PubMedCrossRef 42. Chang LL, Chang TM, Chang CY: Variable gene cassette patterns of class 1 integron-associated drug-resistant Escherichia coli in Taiwan. Kaohsiung J Med Sci 2007, 23:273–280.PubMedCrossRef 43. Jouini A, Ben Slama K, Vinue L, Ruiz E, Saenz Y: Detection of unrelated Escherichia coli strains harboring genes of CTX-M-15, OXA-1, and AAC(6′)-Ib-cr enzymes in a Tunisian hospital

and characterization of their integrons and virulence factors. J Chemother 2010, 22:318–323.PubMed 44. Johnson JR, Stell AL, Delavari P, Murray AC, Kuskowski M: Phylogenetic and pathotypic similarities between Escherichia coli isolates from urinary tract infections in dogs and extraintestinal infections in humans. J Infect Dis 2001, 183:897–906.PubMedCrossRef https://www.selleckchem.com/products/sn-38.html 45. Johnson JR, Goullet P, Picard B, Moseley SL, Roberts Nutlin-3 solubility dmso PL: Association of carboxylesterase B electrophoretic pattern with presence and expression of urovirulence factor determinants and antimicrobial

resistance among strains of Escherichia coli that cause urosepsis. Infect Immun 1991, 59:2311–2315.PubMed 46. Peirano G, Pitout JD: Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2011, 35:316–321.CrossRef Competing interest The authors declare that they have no competing interests. Authors’ contributions Conception and design of the study and acquisition of data: HCR, FR, VR, AT, GA. Molecular and genetic studies, molecular analysis: HCR, GA. Analysis of results: HCR, FR, VR, AT, GA. Draft of the manuscript: HCR, FR, BG, AT, GA. Revisiting of the manuscript for important intellectual content: VR, BG, AT and GA. All authors have read and approved the final manuscript.”
“Background Clinical infection due to drug-resistant bacteria is a serious challenge to patient safety [1, 2]. In the United States, methicillin-resistant Staphylococcus aureus (MRSA) is estimated to cause ~19,000 deaths per year [3]. MRSA is also a considerable threat in China, where the resistance ratio among hospital-acquired infections reaches almost 90% [4, 5].